PAHALGAM DIALOGUES ON CANCER
Saturday, 19 August 2023, Pahalgam, Kashmir
We would like to extend an invitation for your participation in this premier practice-transforming programme as well as an industry and government policy forum designed to gather stakeholders and key opinion leaders in the field. The event will showcase a range of experts, including Medical, Radiation, and Surgical and Surgical Robotics oncologists, as well as leaders from the oncology biotechnology and pharmaceutical industries, molecular diagnostic professionals, policy planners from the Health and Pharmaceutical Ministries, representatives from health media outlets, and key health investment professionals.
At “Pahalgam Dialogues on Cancer” (pDOC) , we aim to provide a dynamic platform for productive discussions in oncology around a wide range of topics, including blood biopsies, actionable mutations, immunotherapy, targeted therapies, proton beam, augmented reality, and 5G-enabled surgery.The conference seeks to generate constructive input on practical preventive strategies, improved access to standardised treatment, and management controversies while ensuring the dissemination of clear take-home messages. The conference will span the entire day, with each session providing participants the opportunity to interact with leading experts in the field through short lectures and case-based panel discussions. Your esteemed presence holds immense significance in our collective mission of raising awareness and seeking meaningful preventive strategies towards delivering timely, homogenous diagnosis and cancer treatment to Indian populations and those from other countries seeking the same here increasingly now.
We hope that you will join us to share your insights and expertise, interact with related industry captains and train your management cadres.Kindly confirm your participation at your earliest convenience, as your involvement will be instrumental in shaping this remarkable conference.

CHAIRMAN's MESSAGE
In the run up to ‘Universal Health Coverage’ we would be naive to ignore major obstacles posed by Global inequalities, dynamic Cancer demographics, and upsurge of translational research. I feel these are formidable challenges at worst not impossible to overcome.
Provided we reaffirm our commitment to achieve our goal from time to time, ponder over and embrace nouvelle strategies to drive ‘value’ into this great game. Is why I implore all eminent stake holders in ‘transitioning countries’ like ours to join Us at pDOC.
The valley of shepherd’s lovingly offers its pristine environs as the stage for this academic feast.
Come Ye friends! Participate and Partake.
I wish you happy brainstorming.
PROVISIONAL AGENDA
Radioimmunoconjugates in Cancer Treatment – where, when, how?
Monoclonal antibodies in Cancer Treatment – is this a path worth taking?
A Flexible Future : Transforming the paradigm of HER2 +ve Breast Cancer treatment
Management of HER 2 -ve metastatic breast cancer
SBRT, IORT, ZAPX & beyond
Check point inhibitors – saviours for cancer patients
Optimising treatment strategies in management of 1L mNSCLC
Blood Biopsies should replace tissue diagnosis – is it time already?
Minimal Residual Disease Detection for Solid Tumors – Current Evidence
Robotics and its evolution – can be ignored no more
PIPAC / HIPEC – remarkable drug delivery systems
PROVISIONAL AGENDA
Radioimmunoconjugates in Cancer Treatment – where, when, how?
Monoclonal antibodies in Cancer Treatment – is this a path worth taking?
A Flexible Future : Transforming the paradigm of HER2 +ve Breast Cancer treatment
Management of HER 2 -ve metastatic breast cancer?
SBRT, IORT, ZAPX & beyond
Defining Treatment Landscape in Hodgkin’s Lymphoma with Adcetris
Check point inhibitors – saviours for cancer patients
Optimising treatment strategies in management of 1L mNSCLC
Blood Biopsies should replace tissue diagnosis – is it time already?
Minimal Residual Disease Detection for Solid Tumors – Current Evidence
Robotics and its evolution – can be ignored no more
PIPAC / HIPEC – remarkable drug delivery systems
Strategies – to incorporate expensive cancer treatments in India’s public health system
PROVISIONAL AGENDA
Radioimmunoconjugates in Cancer Treatment – where, when, how?
Monoclonal antibodies in Cancer Treatment – is this a path worth taking?
A Flexible Future : Transforming the paradigm of HER2 +ve Breast Cancer treatment
Management of HER 2 -ve metastatic breast cancer
SBRT, IORT, ZAPX & beyond
Defining Treatment Landscape in Hodgkin’s Lymphoma with Adcetris
Check point inhibitors – saviours for cancer patients
Optimising treatment strategies in management of 1L mNSCLC
Blood Biopsies should replace tissue diagnosis – is it time already?
Minimal Residual Disease Detection for Solid Tumors – Current Evidence
Robotics and its evolution – can be ignored no more
PIPAC / HIPEC – remarkable drug delivery systems
Strategies – to incorporate expensive cancer treatments in India’s public health system

Dr Abdul Rashid Lone

Dr Ajay Bapna

Dr Anusheel Munshi

Dr Aparna Dhar

Dr Ashwin K R
OUR
EMINENT
FACULTY
EMINENT

Dr Ashok Kumar

Dr Ashutosh Gupta

Dr D Raghunadha Rao

Dr Darshana Patil

Dr Deepak Abrol

Dr Feroz Pasha

Dr G K Jadhav

Prof (Dr)Gaurav Aggarwal

Dr G K Rath

Dr Girish Telang

Mr Gopal Agrawal

Mr Hideshi Yamamoto

Dr Javvid Muzzamil

Dr Jyoti Bajpai

Dr K Govind Babu

Dr Manish Singhal

Dr Maqbool Lone

Dr. Mir Mohd. Hussain

Dr P K Das

Dr R Rajkumar

Dr Rajeev Bedi

Prof Rakesh Jalali

Dr Reena Nayyar

Dr Rohit V Nayyar

Dr Ruqaiya Mir

Dr S H Advani

Dr Sachin Almel

Dr Sajad Qazi

Dr Sameer Kaul

Dr Shabnam Bashir

Dr Sheikh Aijaz Aziz

Dr Shekhar Salkar

Dr Soma Shekhar

Dr Sudhir Gupta

DR. (PROF) S K RAWAL

Dr Syed Nissar

Dr Thomas Varughese

Dr Ullas Batra

Dr (Prof) U S Vishal Rao

Dr Vashishth Maniar

Dr Vinay Deshmane

Dr Vineet Talwar

Dr Vinod Raina

Dr Vivek Tandon
OUR
EMINENT
FACULTY
EMINENT

Dr Abdul Rashid Lone

Dr Ajay Bapna

Dr Anusheel Munshi

Dr Aparna Dhar

Dr Ashwin K R

Dr Ashok Kumar

Dr Ashutosh Gupta

Dr D Raghunadha Rao

Dr Darshana Patil

Dr Deepak Abrol

Dr Feroz Pasha

Dr G K Jadhav

Prof (Dr)Gaurav Aggarwal

Dr G K Rath

Dr Girish Telang

Mr Gopal Agrawal

Mr Hideshi Yamamoto

Dr Javvid Muzzamil

Dr Jyoti Bajpai

Dr K Govind Babu

Dr Manish Singhal

Dr Maqbool Lone

Dr. Mir Mohd. Hussain

Dr P K Das

Dr R Rajkumar

Dr Rajeev Bedi

Prof Rakesh Jalali

Dr Reena Nayyar

Dr Rohit V Nayyar

Dr Ruqaiya Mir

Dr S H Advani

Dr Sachin Almel

Dr Sajad Qazi

Dr Sameer Kaul

Dr Shabnam Bashir

Dr Sheikh Aijaz Aziz

Dr Shekhar Salkar

Dr Soma Shekhar

Dr Sudhir Gupta

DR. (PROF) S K RAWAL

Dr Syed Nissar

Dr Thomas Varughese

Dr Ullas Batra

Dr (Prof) U S Vishal Rao

Dr Vashishth Maniar

Dr Vinay Deshmane

Dr Vineet Talwar

Dr Vinod Raina

Dr Vivek Tandon
EXHIBITION HALL
EXHIBITION HALL

SUPPORTERS


























ORGANISING TEAM

Dr. Sameer Kaul
Organizing Chairman
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION

Dr. Feroz Pasha
Organizing Secretary
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION

Mridul Arora
Organizing Secretary
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION

Naveen Ahuja
Organizing Member
Pahalgam Dialogues on Cancer
bcpbf-THE CANCER FOUNDATION

Dr. Shahin Nooreyezdan
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Hospitals, New Delhi

Prof. Rakesh Jalali
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Proton Cancer Centre, Chennai

Dr. G K Jadhav
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Cancer Institute, New Delhi

Dr. P K Das
Organizing Member
Pahalgam Dialogues on Cancer
Apollo Cancer Institute, New Delhi
32108+
People Screened
780+
Financially Assisted
276+
Provided Free Medicine
32108+
780+
276+
People Screened
Financially Assisted
Provided Free Medicine
CERTIFICATIONS
bcpbf-THE CANCER FOUNDATION (BCPBF) is registered under the Societies Registration Act (XXI) 1860, Govt. of NCT of Delhi. Indian donations shall be exempted from Income tax under 80G of Income Tax Act 1961 as applicable.
bcpbf-THE CANCER FOUNDATION (BCPBF) is registered no (231661601) under the Foreign Contribution (Regulation) Act 2010, Govt. of India.